期刊
JOURNAL OF NEUROVIROLOGY
卷 21, 期 6, 页码 623-631出版社
SPRINGER
DOI: 10.1007/s13365-014-0303-1
关键词
Progressive multifocal leukoencephalopathy; Natalizumab; Efalizumab; Rituximab; Mycophenolate mofetil
资金
- PML Consortium
- BiogenIdec
- Novartis
Progressive multifocal leukoencephalopathy (PML) is a rare, complex opportunistic infection of the central nervous system caused by the JC virus. This past decade, PML was increasingly recognized to be associated with the use of immunosuppressive and biologic agents. The risk for PML differs among these agents and remains difficult to quantify because of the complex pathogenesis of PML and the presence of confounding factors. This paper explores and updates the association of PML with different biologic and immunosuppressive agents and proposes an expanded classification system for the risk of PML. We identify three classes of drug that vary by PML risk, latency to infection, and underlying illness. We also review some of the most common agents with known associations to PML and explore risk mitigation strategies that aim to inform the decision-making process for clinicians and patients in the face of the changing incidence of PML and the growing landscape of immunologic agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据